These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34755980)

  • 1. Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate.
    Besch-Stokes JG; Patel MH; Brumfiel CM; Costello CM; Rule W; Rosenthal A; Pittelkow MR; DiCaudo DJ; Mangold AR
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of multiple nodular cutaneous B-cell pseudolymphoma successfully treated with glucocorticoid, methotrexate, and hydroxychloroquine.
    Han B; Liu H; Wang H
    Dermatol Ther; 2022 Nov; 35(11):e15812. PubMed ID: 36088631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-related CD8+ cutaneous pseudolymphoma: efficacy of methotrexate.
    Ingen-Housz-Oro S; Sbidian E; Ortonne N; Penso-Assathiany D; Chambrin V; Bagot M; Bachelez H; Wolkenstein P; Chosidow O
    Dermatology; 2013; 226(1):15-8. PubMed ID: 23343593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab.
    Martin SJ; Duvic M
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):286-8. PubMed ID: 21658657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
    Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
    Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination.
    Pham-Ledard A; Vergier B; Doutre MS; Beylot-Barry M
    Dermatology; 2010; 220(2):176-9. PubMed ID: 20029164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Cutaneous Pseudolymphoma: A Systematic Review.
    Miguel D; Peckruhn M; Elsner P
    Acta Derm Venereol; 2018 Mar; 98(3):310-317. PubMed ID: 29136262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of cutaneous B-cell pseudolymphoma to cutaneous B-cell lymphoma.
    Kulow BF; Cualing H; Steele P; VanHorn J; Breneman JC; Mutasim DF; Breneman DL
    J Cutan Med Surg; 2002; 6(6):519-28. PubMed ID: 12404039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment.
    Balode D; Beļajeva L; Ruesseler V; Quaas A; Lejniece S
    Am J Case Rep; 2020 Jan; 21():e919616. PubMed ID: 31919337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
    Muniesa C; Domingo-Domenech E; Fornons-Servent R; Peñate Y; Estrach MT; Ramón MD; Medina S; Flórez Á; Ortiz-Romero PL; Sánchez-Caminero MP; Torres-Navarro I; Acebo E; Yanguas I; Fernández-de-Misa R; Blanes M; Zayas A; Descalzo MA; Garcia-Doval I; Servitje O
    J Am Acad Dermatol; 2020 Nov; 83(5):1535-1538. PubMed ID: 32682893
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnostic and Therapeutic Challenges.
    Agarwal A; Testi I; Prakash G; Sharma S; Sehgal S; Kapila AT; Gupta N; Lal V; Gupta V; Welch RJ; Park SS;
    Retina; 2020 Dec; 40(12):2417-2423. PubMed ID: 31568065
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistent B Lymphocyte Depletion After an Ultralow Dose of Rituximab for Pemphigus Vulgaris.
    Lazzarotto A; Ferranti M; Meneguzzo A; Sacco G; Alaibac M
    J Investig Allergol Clin Immunol; 2018 Oct; 28(5):347-348. PubMed ID: 30350792
    [No Abstract]   [Full Text] [Related]  

  • 13. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features.
    Baldassano MF; Bailey EM; Ferry JA; Harris NL; Duncan LM
    Am J Surg Pathol; 1999 Jan; 23(1):88-96. PubMed ID: 9888708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in heavily pretreated cutaneous B-cell lymphoma.
    Zinzani PL; Stefoni V; Alinari L; Vianelli N; Baccarani M
    Leuk Lymphoma; 2003 Sep; 44(9):1637-8. PubMed ID: 14565673
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of benign lymphoid hyperplasia of the orbit with rituximab.
    Ho HH; Savar A; Samaniego F; Manning J; Kasyan A; Pro B; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2010; 26(1):11-3. PubMed ID: 20090476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of CD8+ pseudolymphoma after HIV antiviral triple therapy.
    Schartz NE; De La Blanchardiére A; Alaoui S; Morel P; Sigaux F; Vignon-Pennamen MD; Flageul B; Lebbé C
    J Am Acad Dermatol; 2003 Jul; 49(1):139-41. PubMed ID: 12833028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
    Witzig TE; Inwards DJ; Habermann TM; Dogan A; Kurtin PJ; Gross JB; Ananthamurthy A; Ristow KM; Garity JA
    Mayo Clin Proc; 2007 Jun; 82(6):692-9. PubMed ID: 17550749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique.
    Adhikari N; Biswas A; Bakhshi S; Khanna G; Suri V
    Childs Nerv Syst; 2018 Sep; 34(9):1777-1783. PubMed ID: 29744624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: Two case reports.
    Michelerio A; Novario M; Barruscotti S; Vassallo C
    Dermatol Ther; 2019 Jul; 32(4):e12948. PubMed ID: 31025498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.